Response of primary leptomeningeal melanoma to intrathecal recombinant interleukin-2: A case report

Cancer

Volumn 77, Issue 8, 1996, Pages 1544-1550

  Fathallah Shaykh, Hassan M ^a   Zimmerman, Carol ^a   Morgan, Howard ^a   Rushing, Elisabeth ^a   Schold, S Clifford ^a   Unwin, D Hal ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

cerebrospinal fluid; interleukin 2; magnetic resonance imaging; meningeal neoplasms

Indexed keywords

INTERLEUKIN 2;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; HUMAN; INTRATHECAL DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MELANOMA; MENINGIOMA; NATURAL KILLER CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VISUAL FIELD; VISUAL IMPAIRMENT;

EID: 0029865780     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19960415)77:8<1544::aid-cncr18>3.0.co;2-#     Document Type: Article

References (17)

1. Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 1974;30:122-37.
2. Gibson JB, Burrows D, Weir WP. Primary melanoma of the meninges. J Pathol Bacteriol 1957;74:419-38.
3. Meister L, Rackoff W, Arendash-Durand B. Lepto-meningeal melanosis [clinical conference]. Med Pediatr Oncol 1991; 19(1):42-7.
4. Moser RP, Bruner JM, Grimm EA. Biologic therapy for brain tumors. Cancer Bull 1991;43:117-26.
5. Little JR, Dale AJD, Okazaki H. Meningeal carcinomatosis. Clinical manifestations. Arch Neurol 1974;30:138-43.
6. Fischer-Williams M, Bosanquet FD, Daniel PM. Carcinomatosis of the meninges: a report of three cases. Brain 1955;78:42-58.
7. Katz JL, Valsamis MP, Jampel RS. Ocular signs in diffuse carcinomatous meningitis. Am J Ophthalmol 1961;52:681-9.
8. Altrocchi PA, Reinhardt PH, Eckman PB. Blindness and meningeal carcinomatosis. Arch Ophthalmol 1972;88:508-12.
9. Terry TL, Dunphy EB. Metastatic carcinoma in both optic nerves simulating retrobulbar neuritis. Arch Ophthalmol 1933;10:611-4.
10. Kim YS, Resnick JS. Hypoglycorrhachia with meningeal carcinomatosis. Report of two cases. Ann Intern Med 1965; 63:115-21.
11. Heathfield KWG, Williams JRB. Carcinomatosis of the meninges. Some clinical and pathological aspects. BMJ 1956;1:328-30.
12. Grain GO, Karr JP. Diffuse leptomeningeal carcinomatosis. Clinical and pathologic characteristics. Neurology 1955;5: 706-22.
13. Hanisch UK, Neuhaus J, Quirion R, Kettenmann H. Brain infiltration by autoreactive antibodies induced by central interleukin-2 (IL-2) infusion [abstract]. Soc Neurosci 1994;20:954.
14. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-13.
15. White RL, Schwartzentruber DJ, Guleria A, MacFarlane MP, White DE, Tucker E, et al. Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994;74:3212-22.
16. Samlowski WE, Park KJ, Galinsky RE, Ward JH, Schumann GB. Intrathecal administration of interleukin-2 for meningeal carcinomatosis due to malignant melanoma: sequential evaluation of intracranial pressure, cerebrospinal fluid, cytology, and cytokine induction. J Immunother 1993;13:49-54.
17. Heimans JJ, Wagstaff J, Schreuder WO, Wolbers JG, Baars JW, Polman CH, et al. Treatment of leptomeningeal carcinomatosis with continuous intraventricular infusion of recombinant interleukin-2. Surg Neurol 1991;35:244-7.